CancerVax was incorporated, raised $2 million seed funding and executed a Sponsored Research Agreement with UCLA targeting Ewing sarcoma.
CancerVax filed a provisional patent describing technology that forms the basis of our Universal Cancer Treatment Platform.
CancerVax executed a second Sponsored Research Agreement with UCLA to develop the Universal Cancer Treatment Platform.
CancerVax filed a provisional patent application describing a novel messenger RNA (mRNA) approach to DETECT and MARK cancer cells with precision.
CancerVax entered into a research agreement with Flashpoint Therapeutics to perform research on its newly patent-pending Universal Cancer Treatment platform.
CancerVax is led by an experienced team of biotech experts, cancer researchers and marketing executives, who are working with development partners to create its innovative Universal Cancer Treatment Platform.
Principal Scientist
Chief Scientific Advisor
Years of collective
experience